Viridian Therapeutics, Inc.
VRDNNASDAQHealthcare● Active
$15.87
+$0.09(+0.58%)
Market Cap$1.4B
P/E Ratio—
52W High$34.29
52W Low$13.18
Viridian Therapeutics, Inc. (VRDN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VRDN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.90
Est. -$1.06 · +15.1%
Revenue
$0.00B
Est. $0.00B · +290.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
VRDN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$1.03 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$1.06 | -$0.90 | +15.1% | $0.00B | $0.00B | +290.8% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.90 | -$1.08 | -20.0% | $0.00B | $0.02B | -99.3% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.82 | -$0.34 | +58.5% | $0.07B | $0.02B | +348.1% |
| — Q3 FY2025 | Aug 6, 2025 | -$1.00 | -$1.00 | +0.0% | $0.00B | — | — |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.95 | -$0.87 | +8.4% | $0.00B | $0.00B | +63.3% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$1.05 | -$0.81 | +22.9% | $0.00B | $0.00B | +44.0% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$1.06 | -$1.15 | -8.5% | $0.00B | $0.00B | +72.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$1.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.90
EPS Est.
-$1.06
EPS Surpr.
+15.1%
Revenue
$0.00B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$1.08
EPS Est.
-$0.90
EPS Surpr.
-20.0%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.82
EPS Surpr.
+58.5%
Revenue
$0.07B
Q3 FY2025
Aug 6, 2025
EPS Actual
-$1.00
EPS Est.
-$1.00
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.87
EPS Est.
-$0.95
EPS Surpr.
+8.4%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.81
EPS Est.
-$1.05
EPS Surpr.
+22.9%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$1.15
EPS Est.
-$1.06
EPS Surpr.
-8.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.95 | $-0.28 | $0.02 | 2 |
| Q3 FY2027 | $-1.98 | $-0.58 | $0.04 | 2 |
| Q2 FY2027 | $-2.21 | $-0.64 | $0.04 | 2 |
| Q1 FY2027 | $-2.81 | $-0.82 | $0.05 | 3 |
| Q4 FY2026 | $-3.05 | $-0.89 | $0.06 | 3 |
| Q3 FY2026 | $-1.08 | $-0.95 | $-0.81 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.1B | $0.3B | 7 |
| Q3 FY2027 | $0.0B | $0.1B | $0.2B | 4 |
| Q2 FY2027 | $0.0B | $0.1B | $0.2B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.1B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +15.1% | $14.06 | $18.75 | +33.36% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -20.0% | $28.94 | $29.49 | +1.90% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +58.5% | $22.55 | $24.42 | +8.29% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +0.0% | $17.44 | $17.20 | -1.38% |
| ▲ Q2 FY2025 | May 6, 2025 | +8.4% | $13.12 | $12.03 | -8.31% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +22.9% | $15.53 | $15.29 | -1.55% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -8.5% | $25.71 | $22.43 | -12.76% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -14.6% | $15.40 | $15.12 | -1.82% |
Q2 FY2026+33.36%
Report Date
May 5, 2026
EPS Beat/Miss
+15.1%
Price Before
$14.06
Price After
$18.75
Q1 FY2026+1.90%
Report Date
Feb 26, 2026
EPS Beat/Miss
-20.0%
Price Before
$28.94
Price After
$29.49
Q4 FY2025+8.29%
Report Date
Nov 5, 2025
EPS Beat/Miss
+58.5%
Price Before
$22.55
Price After
$24.42
Q3 FY2025-1.38%
Report Date
Aug 6, 2025
EPS Beat/Miss
+0.0%
Price Before
$17.44
Price After
$17.20
Q2 FY2025-8.31%
Report Date
May 6, 2025
EPS Beat/Miss
+8.4%
Price Before
$13.12
Price After
$12.03
Q1 FY2025-1.55%
Report Date
Feb 27, 2025
EPS Beat/Miss
+22.9%
Price Before
$15.53
Price After
$15.29
Q4 FY2024-12.76%
Report Date
Nov 12, 2024
EPS Beat/Miss
-8.5%
Price Before
$25.71
Price After
$22.43
Q3 FY2024-1.82%
Report Date
Aug 8, 2024
EPS Beat/Miss
-14.6%
Price Before
$15.40
Price After
$15.12
Avg Beat Reaction+6.08%
Avg Miss Reaction-4.23%
Beat Rate5 / 8 quarters
Largest Move+33.36% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VRDN ends December
Viridian Therapeutics, Inc. (VRDN) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.90 — beating the analyst consensus of $-1.06 by +15.1%. The next VRDN earnings date is expected around September 1, 2026.
Each quarter, investors track VRDN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VRDN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VRDN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VRDN earnings · 5 questionsViridian Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. VRDN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VRDN historically reports after market close (AMC).
VRDN earnings datewhen is VRDN earningsVRDN next earnings datewhen does VRDN report earningsVRDN earnings calendar
▸ Source: FMP · Viridian Therapeutics, Inc. SEC filings · US GAAP · Viridian Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026